Abstract:Objective Glucocorticoid (GC) excess decreases bone mineralization and microarchitecture and lead to reduced bone strength. Both anabolic agent parathroid hormone (PTH) and anti-resorptive agent alendronate (ALN) are used to prevent and treat GC-induced bone loss, yet these bone active agents alter bone turnover by very different mechanisms. Our study was to determine how PTH and ALN alter bone quality following GC excess.Methods Nine-month-old SD male rats were treated with methylprednisolone (5 mg/kg·d) or placebo (CON). Other two groups of GC-treated rats had either PTH(80 μg/kg·d) or ALN(4 mg/kg·d) intervention. All the animals were killed after 3 months, and femur and tibia isolated for indicated detection. Bone quality and quantity measurements were measured by dual x-ray absorptiometry (DEXA) for the degree of bone mineralization, histomorphometry for bone microarchitecture, biochemistry for bone turnover. Osteoblasts isolated from newborn rats were cultured in vitro. Cells were treated with 1) CON: placebo; 2)GC: Dexamethasone 10-5mol/L; 3) ALN: Alendronate 10-7mol/L; 4)PTH: human recombinant parathyroid hormone 10-7mol/L; 5)GC+ALN: Dexamethasone 10-5mol/L+ALN 10-7mol/L; 6)GC+PTH: Dexamethasone 10-5mol/L+ PTH 10-7mol/L. Osteoblast proliferation and osteogenic activity were identified by MTT, alkaline phosphatase detection, calcium nodules were observed by Alizarin red staining, and real-time PCR were performed to monitor the expression of several key genes regulating bone formation and mineralization as FGF23 and SOST.Results Spine and Femur BMD was reduced after GC treatment, and it was restored to CON level with GC+ALN and GC+PTH at site of femur and spine separately (P<0.05). Compared to the CON, GC treatment decreased trabecular bone volume, bone formation rate, mineral apposition rate and serum BGP, but increased osteoclast surface and serum TRAP5b (P<0.05). GC+PTH increased and GC+ALN restored trabecular bone volume to the CON levels (P<0.05 compared to GC). GC+PTH increased bone formation rate and serum BGP compared to GC (P<0.05), while GC+ALN increased mineral apposition rate (P<0.01) and reduced osteoclast surface and serum TRAP5b compared to GC (P<0.05). As to osteoblasts experiments, GC treatment decrease MTT and AKP activity, reduced calcium nodules significantly (P<0.05 compared to CON), however, GC+PTH and GC+ALN promoted osteoblast MTT and AKP to the CON levels, but PTH significantly inhibited the calcium nodules, whereas ALN increased it. Realtime-PCR revealed that SOST and FGF23 were up-regulated by GC treatment (P<0.05 compared to CON), but SOST gene was down-regulated after GC+PTH treatment (P<0.01 compared to GC), while SOST and FGF23 genes were both down-regulated by GC+ALN treatment (P<0.05 compared to GC). Conclusion GC excess increased expression of gene that inhibit osteoblast activity and gene that inhibit mineralization and which were associated with reduced bone formation and bone volume. The addition of both PTH and ALN improved bone mass and bone strength during concurrent GC treatment, with PTH lowering expression of SOST and increasing bone formation; while ALN lowered the expression of SOST and FGF23 and reversed the deterioration of bone mineralization induced by GC excess.

Inhibition of heat shock protein 90 rescues glucocorticoid-induced bone loss through enhancing bone formation

HSP90β Chaperoning SMURF1-mediated LATS Proteasomal Degradation in the Regulation of Bone Formation.

HSP90 promotes osteoclastogenesis by dual-activation of cholesterol synthesis and NF-B signaling

HSP90β promotes osteoclastogenesis by dual-activation of cholesterol synthesis and NF-κB signaling

Heat Shock Protein 90 in Neurodegenerative Diseases

Discovery and development of heat shock protein 90 inhibitors.

Inhibition of Heat Shock Protein 90 As a Novel Platform for the Treatment of Cancer.

Phenotypic and Functional Effects of Heat Shock Protein 90 Inhibition on Dendritic Cell

Excess glucocorticoids inhibit murine bone turnover via modulating the immunometabolism of the skeletal microenvironment

Acetylation of Hsp90 Reverses Dexamethasone-Mediated Inhibition of Insulin Secretion.

Inhibition of HSP90β Improves Lipid Disorders by Promoting Mature SREBPs Degradation via the Ubiquitin-proteasome System

Tanshinol Rescues The Impaired Bone Formation Elicited By Glucocorticoid Involved In Klf15 Pathway

Discovery and development of natural heat shock protein 90 inhibitors in cancer treatment

Heat Shock Protein 90 And Role Of Its Chemical Inhibitors In Treatment Of Hematologic Malignancies

Targeting osteoblastic 11β-HSD1 to combat high-fat diet-induced bone loss and obesity

Study on HSP90 Inhibitor of Potentiating Heat-Induced Cell Killing Osteosarcoma Cells

11β-Hydroxysteroid dehydrogenase type 1 selective inhibitor BVT.2733 protects osteoblasts against endogenous glucocorticoid induced dysfunction.

Tanshinol Alleviates Osteoporosis and Myopathy in Glucocorticoid-Treated Rats

Heat Shock Protein 90 is Critical for Regulation of Phenotype and Functional Activity of Human T Lymphocytes and NK Cells.

Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics

Potential therapeutic targets of alendronate and PTH for glucocorticoid-induced bone loss